GRACEcast Breast Cancer Video

cancerGRACE - H. Jack West, MD

Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.

  • 4 minutes 36 seconds
    Should Small Cell Lung Cancer Patients Who Respond to Chemo Receive Consolidation Radiotherapy?

    Dr. Nasser Hanna outlines the possible benefits of consolidation chest radiation for small cell lung cancer patients who respond well to chemotherapy.

    31 July 2014, 7:00 pm
  • 1 minute 55 seconds
    Management of Rare Kidney Tumors

    What puts you at risk for inherited kidney cancer? Dr. Nizar Tannir discusses the signs doctors look for to determine if a kidney cancer patient should be screened for a familial syndrome.

    29 July 2014, 7:00 pm
  • 5 minutes 28 seconds
    Should All Small Cell Lung Cancer Patients Receive Prophylactic Cranial Irradiation?

    The doctors discuss the circumstances under which small cell lung cancer patients should receive prophylactic cranial irradiation.

    27 July 2014, 7:00 pm
  • 2 minutes 3 seconds
    NanoString Treatment for Kidney Cancer

    NanoString Technology may help doctors learn what is driving tumor growth in kidney cancer patients and, therefore, determine what treatments may be most effective for them.

    24 July 2014, 7:00 pm
  • 2 minutes 27 seconds
    Is Necitumumab An Effective Antibody Against EGFR for Patients with Squamous Lung Cancer?

    Dr. Nasser Hanna discusses the SQUIRE trial of the EGFR antibody Necitumumab in patients with squamous lung cancer. Though it achieved a statistical increase in OS, he does not consider it clinically relevant.

    22 July 2014, 7:00 pm
  • 4 minutes 40 seconds
    How is the Heng Criteria Applied to Kidney Cancer Patients?

    Dr. Daniel Heng is the namesake of the Heng Criteria, which evaluates various factors of kidney cancer patients to determine their prognoses.

    20 July 2014, 7:00 pm
  • 7 minutes 28 seconds
    Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?

    The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.

    17 July 2014, 7:00 pm
  • 3 minutes 15 seconds
    What is PD1 and PDL1 in Kidney Cancer?

    Dr. Lauren Harshman explains what PD1 (an immune T-cell) and PDL1 (a protein on the PD1 T-cell) are and how new drugs impact them to fight kidney cancer.

    15 July 2014, 7:00 pm
  • 7 minutes 22 seconds
    Zykadia for ALK Positive Lung Cancer: New Drug, New Hope

    The doctors discuss the new FDA-approved drug for ALK positive lung cancer patients, Zykadia (ceritinib), including the dosage level, potential side effects and the ability of Zykadia to impact brain metastases.

    13 July 2014, 7:00 pm
  • 5 minutes 41 seconds
    No Clear Answer for Non-Clear Cell Kidney Cancer

    Drugs in early stage clinical trials seem to show benefit for non-clear cell kidney cancer, but more trials must take place and patients are desperately needed to enroll in them.

    10 July 2014, 7:00 pm
  • 3 minutes 52 seconds
    What Went Wrong? The Failure of MetMab with Tarceva in Advanced Non-Small Cell Lung Cancer

    "Dead negative," is how Dr. Nasser Hanna describes results of a phase 3 study that examined how patients with high MET expression did on the drug MetMab (onartuzumab).

    8 July 2014, 7:00 pm
  • More Episodes? Get the App